RITUXAN (rituximab) Patient Assistance Program
Don’t let the high cost of brand specialty anti-CD20 therapy stand between you and the treatment you need. We help eligible patients access Rituxan (rituximab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Rituxan (rituximab) is FDA-approved across multiple conditions — non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), pemphigus vulgaris, and others. It is given as an IV infusion (or as Rituxan Hycela for SC administration in some indications).
- Without assistaWithout assistance, brand Rituxan costs commonly run $5,500–$8,500 per IV infusion. Multiple FDA-approved biosimilars (Truxima, Ruxience, Riabni) are available at significantly lower cost.nce, brand Remicade infusions cost commonly run $4,500–$7,000+ each. Multiple FDA-approved biosimilars (Inflectra, Renflexis, Avsola, Ixifi) are available at significantly lower cost.
- Through AffordMyPrescriptions, qualifying patients can access Rituxan (or biosimilar) for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- Multiple FDA-approved rituximab biosimilars provide significant savings — Truxima, Ruxience, and Riabni are widely available at major infusion centers.
What Is Rituxan Prescription Assistance Program?
The Rituxan Prescription Assistance Program is a manufacturer-sponsored initiative that provides Rituxan infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for patients with NHL, CLL, RA, vasculitis, or other rituximab-treated conditions who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology/rheumatology coordination, HBV screening documentation, infusion scheduling, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, brand Rituxan infusions cost roughly $5,500–$8,500 each. Multiple biosimilars are available at significantly lower cost. A Patient Assistance Program is the meaningful path for brand pricing — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (brand) | ~$7,000.00 | Save ~$6,930/dose |
| Per IV infusion (biosimilar) | ~$3,800.00 | Save ~$3,730/dose |
| Rituxan Hycela (SC) | ~$7,500/dose | Save ~$7,430/dose |
| NHL/CLL course (6–8 cycles) | ~$50,000+ | Save ~$49,000+ total |
| RA dosing (every 6 mo) | ~$14,000+/yr | Save ~$13,000+/yr |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Rituxan Prescription Program?
The Patient Assistance Program is free to apply for and provides Rituxan infusions at little or no medication cost if approved. But the process involves detailed applications, prescriber coordination, HBV screening documentation, infusion scheduling, and ongoing renewal management. Our $69.95/month service covers full advocacy. With multiple Rituxan biosimilars available at significantly lower cost, we’ll guide you to the most cost-effective path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Rituxan:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $5,500–$8,500 per infusion (brand) / lower for biosimilars per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Rituxan assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Rituxan Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Rituxan:
Rituxan (rituximab) is an intravenous (IV) anti-CD20 monoclonal antibody used to treat a wide range of B-cell cancers (non-Hodgkin lymphoma, chronic lymphocytic leukemia) and autoimmune diseases (rheumatoid arthritis, GPA, MPA, pemphigus vulgaris). It was the first anti-CD20 antibody approved (1997) and remains a foundational therapy in many regimens.
How Rituxan Works:
Rituxan is a monoclonal antibody that targets the CD20 marker on B-lymphocytes, triggering their destruction through the immune system and direct cell death. In B-cell lymphomas, it eliminates malignant cells, while in autoimmune diseases, it removes B cells responsible for producing harmful autoantibodies. Because B cells take time to repopulate, the therapeutic effects of the treatment can last for several months.
Form and use:
Administered as an IV infusion in clinical settings, Rituxan dosing is highly specific to the condition being treated, ranging from weekly cycles for lymphoma to twice-yearly sessions for rheumatoid arthritis. A subcutaneous version, Rituxan Hycela, is also available for certain indications. To ensure safety, premedication is provided to reduce the risk of infusion reactions during the procedure.
Generic availability:
As of 2026, multiple FDA-approved biosimilars for Rituxan (rituximab) are available in the U.S., including Truxima, Ruxience, and Riabni. these biosimilars typically provide a significantly lower-cost alternative to the brand-name drug. The decision to use a specific biosimilar is usually determined by the prescribing physician, the infusion center’s specific contracts, and the patient’s insurance plan.
Warnings:
Rituxan carries boxed warnings for severe infusion and skin reactions, as well as the risk of Hepatitis B reactivation and a rare brain infection called PML. Screening for Hepatitis B is mandatory before starting therapy. Other serious risks include infections, kidney toxicity, and tumor lysis syndrome; additionally, patients must avoid live vaccines during and shortly after treatment.
FAQ (Frequently Asked Questions)
How Much Does Rituxan Cost Without Insurance?
Per-infusion costs commonly run $5,500–$8,500 for brand Rituxan. Biosimilars are typically 30–40% cheaper. NHL/CLL courses commonly total $50,000+ over 6–8 cycles. Through AffordMyPrescriptions, qualifying patients receive Rituxan (or biosimilar) at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Are Biosimilars To Rituxan The Same Medicine?
Biosimilars (Truxima, Ruxience, Riabni) are FDA-approved as highly similar to and clinically equivalent to brand Rituxan (rituximab). They contain the same active ingredient and produce the same clinical results. Whether your infusion is filled as brand or biosimilar depends on your prescriber and infusion site — for many patients, the biosimilar at lower cost is the right path.Biosimilars (Inflectra, Renflexis, Avsola, Ixifi) are FDA-approved as highly similar to and clinically equivalent to brand Remicade (infliximab). They contain the same active ingredient and produce the same clinical results. Whether your infusion is filled as brand or biosimilar depends on your prescriber and infusion site — for many patients, the biosimilar at significantly lower cost is the right path
What Is Rituxan Hycela?
Rituxan Hycela is a subcutaneous (under-the-skin) formulation of rituximab combined with hyaluronidase enzyme to enable SC absorption. It is given over 5–7 minutes (compared to several hours for the IV form). It is approved for some lymphoma indications, but not for all conditions where IV Rituxan is used.
Why Is HBV Screening Required Before Starting Rituxan?
All anti-CD20 antibodies carry a risk of reactivating chronic or resolved hepatitis B virus (HBV) infection — which can lead to fulminant hepatitis. Before starting Rituxan, you’ll be screened for HBV (HBsAg and anti-HBc), and if you have evidence of prior infection, you’ll typically be co-treated with an antiviral throughout therapy and for several months after.
Can I Get Rituxan Through The PAP If I Have Medicare?
Yes. Medicare beneficiaries can typically qualify for Rituxan Patient Assistance, especially if you face significant out-of-pocket costs under medical or pharmacy benefits. The manufacturer’s commercial copay assistance program is reserved for commercially insured patients only. |
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — switching to a Rituxan biosimilar at significantly lower cost, the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation, HealthWell Foundation, the Leukemia & Lymphoma Society Co-Pay Assistance Program, or the Arthritis Foundation, or asking your prescriber whether a different anti-CD20 antibody would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Rituxan, our team may be able to help you access assistance programs — or guide you to the cheaper biosimilar path if it is the better fit. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.